A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
This multicenter, randomized, open-label study will evaluate the immune response to vaccines
 (tetanus toxoid [TT]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide
 vaccine [23-PPV] either unboosted or boosted with 13-valent pneumococcal conjugate vaccine
 [13-PCV], influenza vaccine, keyhole limpet hemocyanin [KLH]) after administration of a dose
 of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS).
Inclusion Criteria:

 -  Diagnosis of RMS in accordance with the revised McDonald criteria

 -  Received at least one previous immunization against TT or tetanus and diphtheria
 (DT/Td) or tetanus, diphtheria, and acellular pertussis (DTaP/Tdap)

 -  Expanded Disability Status Scale (EDSS) at Screening from 0 to 5.5 points, inclusive

 -  For sexually active female participants of reproductive potential, use of reliable
 means of contraception

 Exclusion Criteria:

 -  Contraindications for or intolerance to oral or IV corticosteroids, including IV
 methylprednisolone, according to the country label

 -  Known presence of other neurologic disorders

 -  Treatment with any investigational agent within 24 weeks of screening or 5 half-lives
 of the investigational drug, whichever is longer, or treatment with any experimental
 procedure for multiple sclerosis